About: Hydroxychloroquine and Azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Hydroxychloroquine and Azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Hydroxychloroquine and Azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trial
Creator	Raoult, Didier Colson, Philippe Rolain, Jean-Marc Gautret, Philippe Brouqui, Philippe Parola, Philippe Lagier, Jean-Christophe Doudier, Barbara Courjon, Johan Hoang, Van Mailhe, Morgane Scola, Bernard Chabrière, Eric Dupont, Tissot Giordanengo, Valérie Honoré, Stéphane Meddeb, Line Vieira, Vera
source	MedRxiv
abstract	Background Chloroquine and Hydroxychloroquine have been found to be efficient on COV-19, and reported to be efficient in Chinese patients infected by this virus. We evaluate the role of Hydroxychloroquine on respiratory viral loads. Patients and methods Patients were included in a single arm protocol to receive 600mg of hydroxychloroquine daily and their viral load in nasal swabs was tested daily. Depending on their clinical presentation azithromycin was added to the treatment. Untreated patients from another center and cases refusing the protocol were included as negative control. Presence and absence of virus at Day-6 was considered the end point. Results Twenty cases were treated in this study and showed a significant reduction of the viral carriage at D-6 compared to controls, and much lower than reported average carrying duration of untreated patients in the literature. Azithromycin added to Hydroxychloroquine was significantly more efficient for virus elimination. Conclusion : Hydroxychloroquine is significantly associated with viral load reduction/disappearance in patients with COVID-19 and its effect is reinforced by Azithromycin.
has issue date	2020-03-20(xsd:dateTime)
bibo:doi	10.1101/2020.03.16.20037135
has license	medrxiv
sha1sum (hex)	4da0f2ec885057de83d5eef38a770177f91d9f7e
schema:url	https://doi.org/10.1101/2020.03.16.20037135
resource representing a document's title	Hydroxychloroquine and Azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trial
resource representing a document's body	covid:4da0f2ec885057de83d5eef38a770177f91d9f7e#body_text
is schema:about of	named entity 'SARS-COV-2' named entity 'REPORTED' named entity 'RESPIRATORY' named entity 'hydroxychloroquine' named entity 'Chloroquine' named entity 'hydroxychloroquine' named entity 'randomized clinical trial' named entity 'Hydroxychloroquine' named entity 'viruses' named entity 'SARS-CoV-2' named entity 'Marseille' named entity 'Marseille' named entity 'nasopharyngeal swab' named entity 'preprint' named entity 'serum' named entity 'respiratory tract infections' named entity 'upper respiratory tract infection' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'medRxiv' named entity 'supernatant' named entity 'primary endpoint' named entity 'RT-PCR' named entity 'URTI' named entity 'rhinitis' named entity 'chronic diseases' named entity 'control group' named entity 'dose-dependent' named entity 'control group' named entity 'SARS-CoV' named entity 'Wuhan' named entity 'chloroquine' named entity 'hydroxychloroquine' named entity 'synergistic effect' named entity 'French Ministry of Health' named entity 'medRxiv' named entity 'Darmstadt' named entity 'hydroxychloroquine' named entity 'preprint' named entity 'hydroxychloroquine' named entity 'administrated' named entity 'preprint' named entity 'preprint' named entity 'hydroxychloroquine' named entity 'asymptomatic carriers' named entity 'WHO' named entity 'Symptomatic treatment' named entity 'peer review' named entity 'virus' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'Marseille' named entity 'case-fatality rate' named entity 'treatment group' named entity 'COVID' named entity 'antiviral treatment' named entity 'myalgia' named entity 'hydroxychloroquine' named entity 'preprint' named entity 'Hydroxychloroquine' named entity 'viral shedding' named entity 'preprint' named entity 'Tropheryma whipplei' named entity 'preprint' named entity 'preprint' named entity 'Hitachi' named entity 'inoculated' named entity 'medRxiv'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software